FDA Weighs Options After Teva Wins Risperdal Spat

Law360, New York (April 11, 2008, 12:00 AM EDT) -- Teva Pharmaceutical Industries Ltd. has won the exclusive right to sell its generic version of Johnson & Johnson's blockbuster drug Risperdal in the U.S. for six months beginning at the end of June, after a judge ruled in Teva's favor in its suit against the U.S. Food and Drug Administration.

U.S. District Judge Royce C. Lamberth signed off Friday on an order barring the FDA from approving any abbreviated new drug applications for generic risperidone tablets until Teva's 180 days of marketing exclusivity expire. Judge Lamberth...
To view the full article, register now.